Saurashtra News

Diffuse Large B-Cell Lymphoma Market

DelveInsight’s Diffuse Large B-cell Lymphoma market report offers comprehensive coverage of the current treatment practices, emerging drugs, Diffuse Large B-cell Lymphoma market share of individual therapies, and current and forecasted Diffuse Large B-cell Lymphoma market size from 2018 to 2030, segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Key Features of the Diffuse Large B-Cell Lymphoma Market Report

• According to DelveInsight’s, Diffuse Large B-Cell Lymphoma epidemiology insights, the total incident cases was estimated to be 71,045 in the 7MM in 2020.

• Among the EU5 countries, Germany had the highest Diffuse Large B-Cell Lymphoma incident cases while Spain had the lowest in 2020.

• Key companies across the globe such as Bristol-Myers Squibb, Seattle Genetics, Takeda, ADC Therapeutics, Morphosys, Incyte, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer, Janssen, Pharmacyclics, and others are involved in the development of novel therapies for the treatment of Diffuse Large B-Cell Lymphoma. 

• Key pipeline therapies in the Diffuse Large B-Cell Lymphoma market include Breyanzi, Brentuximab Vedotin, Loncastuximab Tesirine, Ublituximab + Umbralisib, Aliqopa, DPX-Survivac, AUTO3, CLR 131, P + RCHOP, and several others.

• Breyanzi (Lisocabtagene maraleucel; Bristol-Myers Squibb) is a CAR T-cell therapy that targets CD19, a surface glycoprotein expressed during normal B-cell development. Breyanzi has received Priority Medicines (PRIME) designation in the European Union for R/R DLBCL. 

• AUTO3 (Autolus Therapeutics) is a first-in-class bicistronic CAR T-cell therapy that contains two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity.

• Obinutuzumab (Hoffmann-La Roche) is a monoclonal antibody that has been engineered to bind to CD20, a protein expressed on certain B-cells but not on stem or plasma cells.

Want to know how to treat diffuse large b-cell lymphoma? To know the answer request sample @ Diffuse Large B-Cell Lymphoma Treatment Guidelines

The Diffuse Large B-Cell Lymphoma market report also discusses current Diffuse Large B-cell Lymphoma treatment practices/algorithms, Diffuse Large B-Cell Lymphoma market drivers, Diffuse Large B-Cell Lymphoma market barriers, and unmet medical needs. 

Diffuse Large B-Cell Lymphoma: Overview

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It occurs when B-lymphocytes become abnormal. It is a mature B-cell neoplasm that develops from the germinal center and post germinal center B-cells. Primary Mediastinal Large B-Cell Lymphoma and Primary Effusion Lymphoma (PEL) are the rare subtypes of DLBCL.

Diffuse Large B-Cell Lymphoma Epidemiology Segmentation

The Diffuse Large B-Cell Lymphoma report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Diffuse Large B-Cell Lymphoma Total Incident Cases

• Diffuse Large B-Cell Lymphoma Gender-Specific Cases

• Diffuse Large B-Cell Lymphoma Age-Specific Cases 

• Diffuse Large B-Cell Lymphoma Type-Specific Cases

• Diffuse Large B-Cell Lymphoma Stage-Specific Cases

Diffuse Large B-Cell Lymphoma Treatment Landscape

The treatment option for Diffuse Large B-Cell Lymphoma is determined by the symptoms, age, and rate of growth, as well as whether patients experience various patterns of recurrence necessitating subsequent lines of rescue therapy. Chemotherapy, radiation, and immunotherapy are all treatment options for B-cell lymphoma. Chemotherapy is the primary treatment for most types of B-cell NHL. 

Diffuse Large B-Cell Lymphoma Market

The Diffuse Large B-Cell Lymphoma market size was found to be USD 3,668 million in the 7MM in 2020.

The Diffuse Large B-Cell Lymphoma market size is anticipated to increase during the forecast period (2021–2030), owing to the launch of upcoming therapies such as Breyanzi, Brentuximab Vedotin, Loncastuximab Tesirine, and others.

Get a detailed analysis of the DLBCL market size @ Diffuse Large B-Cell Lymphoma Market Share

Diffuse Large B-Cell Lymphoma Pipeline Therapies and Key Companies 

• Lisocabtagene maraleucel: Bristol-Myers Squibb

• Brentuximab Vedotin: Seattle Genetics/Takeda

• Loncastuximab Tesirine: ADC Therapeutics

• Ublituximab + Umbralisib: TG Therapeutics

• Aliqopa: Bayer

• DPX-Survivac: IMV, inc. & Merck

• AUTO3: Autolus Therapeutics

• CLR 131: Cellectar Bioscience

• P + RCHOP: Merck Sharp & Dohme 

Diffuse Large B-Cell Lymphoma Market Drivers

• Rising Incidence among Aging population

• Increase in R&D

• CAR-T therapies approvals

Diffuse Large B-Cell Lymphoma Market Barriers

• Availability of defined DLBCL diagnostic tools

• Delay in DLBCL Diagnosis

• High cost of DLBCL treatment

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

DLBCL Key Companies: Bristol-Myers Squibb, Seattle Genetics, Takeda, ADC Therapeutics, Morphosys, Incyte, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer, Janssen, Pharmacyclics, among others. 

DLBCL Key Pipeline Therapies: Breyanzi, Brentuximab Vedotin, Loncastuximab Tesirine, Ublituximab + Umbralisib, Aliqopa, DPX-Survivac, AUTO3, CLR 131, P + RCHOP,and others.

DLBCL Segmentation: By Geography, By DLBCL therapies

Analysis: Comparative and conjoint analysis of DLBCL emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Non-Hodgkins Lymphoma Market

Get a comprehensive analysis of Non-Hodgkins Lymphoma pipeline therapies and key companies such as ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Celgene Corp., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/